½ÃÀ庸°í¼­
»óǰÄÚµå
1530760

¿ø°ÝÀÇ·á ½ÃÀå ¿¹Ãø(-2030³â) : ÄÄÆ÷³ÍÆ®, ÄÉ¾î ¸ðµ¨, ¸ð´Þ¸®Æ¼, Á¦°ø ¸ðµå, ±â¼ú, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº° ¼¼°è ºÐ¼®

Telemedicine Market Forecasts to 2030 - Global Analysis By Component, Care Model, Modality, Delivery Mode, Technology, Application, End User and Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ ¿ø°ÝÀÇ·á ½ÃÀåÀº 2024³â¿¡ 1,221¾ï ´Þ·¯¸¦ Â÷ÁöÇÏ°í ¿¹Ãø ±â°£ Áß CAGRÀº 18.2%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 3,330¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Åë½Å ÀÇ·á´Â Åë½Å ±â¼úÀ» ÀÌ¿ëÇØ ¿ø°ÝÁö¿¡¼­ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ȯÀÚ´Â È­»ó ÅëÈ­, ÀüÈ­, ¾ÈÀüÇÑ ¸Þ½Ã¡ Ç÷§ÆûÀ» ÅëÇØ ÀÇ·á Àü¹®°¡¿Í »ó´ãÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á´Â Áø´Ü, Ä¡·á, °æ°ú °üÂû, ¸¸¼ºÁúȯ ¸ð´ÏÅ͸µ µî ´Ù¾çÇÑ ¸ñÀûÀ¸·Î Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á´Â ƯÈ÷ Áö¹æÀ̳ª °Åµ¿ÀÌ ºÒÆíÇÑ È¯Àڵ鿡°Ô ÀÇ·á Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í, À̵¿ ½Ã°£°ú ºñ¿ëÀ» Àý°¨Çϸç, ÀÇ·á ÀÚ¿øÀ» º¸´Ù È¿À²ÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)¿¡ µû¸£¸é 2019-2021³â±îÁö ÀÇ»çÀÇ ¿ø°ÝÀÇ·á ÀÌ¿ë·üÀº 15.4%¿¡¼­ 86.5%·Î Áõ°¡Çß½À´Ï´Ù.

ºñ¿ë È¿À²ÀûÀÎ ÀÇ·á¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

¿ø°ÝÀÇ·á´Â º´¿ø ¹æ¹®, ±³Åëºñ, ÀÇ·á ½Ã¼³¿¡ ´ëÇÑ ºÎ´ãÀ» ÃÖ¼ÒÈ­ÇÏ¿© Àüü ÀÇ·áºñ¸¦ Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á ÀÚ¿øÀ» º¸´Ù È¿À²ÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ°í, ȯÀÚ´Â Áý¿¡¼­ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¿ø°Ý Áø·á¿Í ¸ð´ÏÅ͸µÀÌ °¡´ÉÇϹǷΠ¸¸¼ºÁúȯÀ» º¸´Ù È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ°í, °í°¡ÀÇ ÀÀ±Þ °³ÀÔÀÇ Çʿ伺À» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºñ¿ë È¿À²¼ºÀº ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¸ðµÎ¿¡°Ô ƯÈ÷ ¸Å·ÂÀûÀ̸ç, ¿ø°ÝÀÇ·á ¼Ö·ç¼ÇÀÇ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

µ¥ÀÌÅÍ º¸¾È ¹× °³ÀÎÁ¤º¸ º¸È£¿¡ ´ëÇÑ ¿ì·Á

¿ø°ÝÀÇ·á´Â ±â¹Ð¼ºÀÌ ³ôÀº ȯÀÚ Á¤º¸¸¦ Àü¼ÛÇϰí ÀúÀåÇϹǷΠµ¥ÀÌÅÍ À¯Ãâ ¹× ¹«´Ü ¾×¼¼½ºÀÇ À§ÇèÀÌ ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â HIPAA¿Í °°Àº ±ÔÁ¦¸¦ ÁؼöÇØ¾ß Çϴµ¥, µðÁöÅРȯ°æ¿¡¼­´Â À̸¦ ÁؼöÇϱⰡ ½±Áö ¾Ê½À´Ï´Ù. ȯÀÚµéÀº °³ÀÎ °Ç°­ Á¤º¸ÀÇ º¸¾È¿¡ ´ëÇÑ ºÒ¾È°¨À¸·Î ÀÎÇØ ¿ø°ÝÀÇ·á ¼­ºñ½º ÀÌ¿ëÀ» ÁÖÀúÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ì·Á¸¦ ÇØ¼ÒÇϱâ À§Çؼ­´Â °­·ÂÇÑ »çÀ̹ö º¸¾È ´ëÃ¥°ú ¸íÈ®ÇÑ °³ÀÎÁ¤º¸ º¸È£Á¤Ã¥ÀÌ ÇÊ¿äÇϸç, À̸¦ µµÀÔÇÏ´Â µ¥¿¡´Â ºñ¿ë°ú º¹À⼺ÀÌ ¼ö¹ÝµÇ¹Ç·Î ½ÃÀå ¼ºÀåÀÌ µÐÈ­µÉ ¼ö ÀÖ½À´Ï´Ù.

½ÅÈï ±¹°¡¿¡¼­ÀÇ Ã¤Åà Ȯ´ë

½ÅÈï ±¹°¡¿¡¼­ÀÇ ¿ø°ÝÀÇ·á º¸±Þ È®´ë´Â ½ÃÀå È®´ëÀÇ Å« ±âȸ°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. À̵é Áö¿ª, ƯÈ÷ ³óÃÌ Áö¿ª¿¡¼­´Â ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º¿¡ ¹®Á¦°¡ ÀÖ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¿ø°ÝÀÇ·á´Â ¿ø°Ý Áø·á¿Í Àü¹®Àû Á¢±ÙÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ °ÝÂ÷¸¦ ÇØ¼ÒÇÒ ¼ö ÀÖ½À´Ï´Ù. °³¹ßµµ»ó±¹¿¡¼­´Â ½º¸¶Æ®ÆùÀÇ º¸±Þ°ú ÀÎÅÍ³Ý ÀÎÇÁ¶ó°¡ °³¼±µÇ¸é¼­ ¿ø°ÝÀÇ·áÀÇ µµÀÔÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÀÌµé ±¹°¡ÀÇ Á¤ºÎ¿Í ÀÇ·á ±â°üµéÀº ¿ø°ÝÀÇ·á°¡ ÀÇ·á ¼­ºñ½º¸¦ È¿À²ÀûÀ¸·Î °³¼±ÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¿ø°ÝÀÇ·á °ø±ÞÀÚ¿Í ±â¼ú¿¡ »õ·Î¿î ½ÃÀåÀ» ¿­¾î ¼¼°è ½ÃÀåÀÇ Çõ½Å°ú ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.

±â¼úÀû ÇѰè

ƯÈ÷ Áö¹æÀ̳ª ¿Üµý Áö¿ª¿¡¼­´Â ÀÎÅÍ³Ý ¿¬°á ºÎÁ·°ú °°Àº ¹®Á¦·Î ÀÎÇØ È­»ó Áø·á¿Í µ¥ÀÌÅÍ Àü¼ÛÀÇ ÁúÀÌ ¶³¾îÁú ¼ö ÀÖ½À´Ï´Ù. ÀϺΠȯÀÚ, ƯÈ÷ ³ëÀεéÀº ¿ø°ÝÀÇ·á ±â¼úÀ» »ç¿ëÇÏ´Â µ¥ ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖÀ¸¸ç, µµÀÔÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á Ç÷§ÆûÀÌ Ç¥ÁØÈ­µÇÁö ¾Ê°í ¼­·Î ´Ù¸¥ ½Ã½ºÅÛ °£ÀÇ »óÈ£¿î¿ë¼º ¹®Á¦·Î ÀÎÇØ ÀÇ·á ¼­ºñ½º Á¦°øÀÌ ÆÄÆíÈ­µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀ¸·Î ½Åü °Ë»ç¸¦ ÇÒ ¼ö ¾ø±â ¶§¹®¿¡ ƯÁ¤ ÀÇ·á Àü¹® ºÐ¾ß¿¡¼­´Â ¿ø°ÝÀÇ·áÀÇ ¹üÀ§°¡ Á¦ÇѵǾî Àü¹ÝÀûÀÎ ¿µÇâ·Â°ú äÅ÷üÀÌ ¶³¾îÁú ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ :

COVID-19 ÆÒµ¥¹ÍÀº ¿ø°ÝÀÇ·áÀÇ º¸±ÞÀ» Å©°Ô °¡¼ÓÈ­Çß½À´Ï´Ù. Æó¼â ¹× »çȸÀû °Å¸®µÎ±â Á¶Ä¡·Î ÀÎÇØ ¿ø°ÝÀÇ·á Á¦°øÀÌ ÇÊ¿äÇØÁ³°í, ¿ø°ÝÀÇ·áÀÇ ÀÌ¿ëÀÌ ±Þ°ÝÈ÷ È®´ëµÇ¾ú½À´Ï´Ù. ±ÔÁ¦ À庮ÀÌ ¿ÏÈ­µÇ°í ¿ø°ÝÀǷḦ ÃËÁøÇϱâ À§ÇØ »óȯ Á¤Ã¥ÀÌ Á¶Á¤µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â À§±â »óȲ¿¡¼­µµ ÀÇ·á ¼­ºñ½º Á¢±Ù¼ºÀ» À¯ÁöÇÒ ¼ö ÀÖ´Â ¿ø°ÝÀÇ·áÀÇ ÀáÀç·ÂÀ» ºÎ°¢½ÃÄÑ ÀÇ·á ¼­ºñ½º Á¦°ø ¸ðµ¨¿¡ Áö¼ÓÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

¿¹Ãø ±â°£ Áß ½Ç½Ã°£(µ¿±âÈ­) ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Ç½Ã°£(µ¿±â½Ä) ºÎ¹®Àº ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Áï°¢ÀûÀ¸·Î ¾ó±¼À» ¸Â´ë°í »óÈ£ ÀÛ¿ëÇÒ ¼ö ÀÖÀ¸¹Ç·Î ¿ø°ÝÀÇ·á ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ¹æ½ÄÀº ´ë¸é Áø·á¿Í À¯»çÇÑ ¹æ½ÄÀ¸·Î ½Ç½Ã°£ Áø´Ü, Ä¡·á °áÁ¤, ȯÀÚ ±³À°À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ƯÈ÷ ÀÀ±ÞÀÇ·á, Á¤½Å°Ç°­ ¼­ºñ½º, Àü¹®ÀÇ Áø·á¿¡ ƯÈ÷ È¿°úÀûÀÔ´Ï´Ù. ¿Âµð¸Çµå ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í È­»óȸÀÇ ±â¼ú¿¡ ´ëÇÑ È¯ÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¸ðµÎÀÇ ÆíÀǼº Çâ»óÀ¸·Î ÀÌ ºÎ¹®ÀÇ ¿ìÀ§¸¦ Á¡ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¿¹Ãø ±â°£ Áß ¼ÒÇÁÆ®¿þ¾î ºÐ¾ß´Â °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºü¸¥ ±â¼ú ¹ßÀü°ú ÇコÄɾîÀÇ µðÁöÅÐÈ­·Î ÀÎÇØ ¼ÒÇÁÆ®¿þ¾î ºÐ¾ß´Â ¿ø°ÝÀÇ·á ½ÃÀå¿¡¼­ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °¡»ó Áø·á Ç÷§Æû, ÀüÀÚ ÀÇ·á ±â·Ï ÅëÇÕ, AI ±â¹Ý Áø´Ü Åø¿Í °°Àº ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀº Á¡Á¡ ´õ Á¤±³ÇØÁö°í »ç¿ëÀÚ Ä£È­ÀûÀ¸·Î ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¿ø°ÝÀÇ·á ¼­ºñ½ºÀÇ È¿À²¼º°ú È¿°ú¼ºÀ» ³ôÀ̰í ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ¿Í ȯÀÚ ¸ðµÎÀÇ °æÇèÀ» Çâ»ó½Ãų °ÍÀÔ´Ï´Ù. ¶ÇÇÑ ÇコÄÉ¾î ºÐ¾ß¿¡¼­ µ¥ÀÌÅÍ ºÐ¼®°ú AI¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÷´Ü ¿ø°ÝÀÇ·á ¼ÒÇÁÆ®¿þ¾î¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

ÃÖ´ë ½ÃÀå Á¡À¯À²À» °¡Áø Áö¿ª

ºÏ¹Ì°¡ ¿ø°ÝÀÇ·á ½ÃÀå¿¡¼­ ¿ìÀ§¸¦ Á¡Çϰí ÀÖ´Â ¹è°æ¿¡´Â ¸î °¡Áö ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ÀÇ·á ÀÎÇÁ¶ó°¡ Àß ¹ß´ÞµÇ¾î ÀÖ°í, ±â¼ú µµÀÔ·üÀÌ ³ô½À´Ï´Ù. ƯÈ÷ ¹Ì±¹ÀÇ °æ¿ì, Á¤ºÎÀÇ ±ÔÁ¦¿Í »óȯ Á¤Ã¥ÀÌ ¿ìÈ£ÀûÀ̾ ¿ø°ÝÀÇ·áÀÇ È°¿ëÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿ø°ÝÀÇ·á ±â¾÷ÀÇ Á¸Àç¿Í ÇコÄɾî IT¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ°¡ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ³ôÀº ¸¸¼ºÁúȯ À¯º´·ü°ú °í·ÉÈ­ Ãß¼¼·Î ÀÎÇØ ¿ø°ÝÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ºÏ¹ÌÀÇ ¿ø°ÝÀÇ·á µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, ´çºÐ°£ ºÏ¹Ì ¿ø°ÝÀÇ·á ½ÃÀåÀÌ ÁÖµµ±ÇÀ» ÀâÀ» °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿ø°ÝÀÇ·á ½ÃÀå¿¡¼­ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü, ÀÎÅÍ³Ý º¸±Þ·ü Áõ°¡, ÀÇ·áºñ Áõ°¡, ƯÈ÷ Àεµ¿Í Áß±¹°ú °°Àº Àα¸ ¹ÐÁý ±¹°¡¿¡¼­ ¿ø°ÝÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. µðÁöÅÐ ÇコÄɾ ÃËÁøÇϱâ À§ÇÑ Á¤ºÎÀÇ ±¸»ó°ú COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ¿ø°ÝÀÇ·á ¼­ºñ½º µµÀÔµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖÀ¸¸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿ø°ÝÀÇ·á ¼­ºñ½º È®´ë¿¡ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ Áö¿ªÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

¹«·á Ä¿½ºÅ͸¶ÀÌÁî ¼­ºñ½º

º» ¸®Æ÷Æ®¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ¾Æ·¡ÀÇ ¹«·á Ä¿½ºÅ͸¶ÀÌÁî ¿É¼Ç Áß Çϳª¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. :

  • ±â¾÷ °³¿ä
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀû ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3»ç)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(ÃÖ´ë 3»ç)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡ÀÇ ½ÃÀå Ã߻ꡤ¿¹Ãø¡¤CAGR(ÁÖ : Ÿ´ç¼º È®Àο¡ µû¶ó ´Ù¸§)
  • °æÀï º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¿ªÀû ÇÁ·¹Áð½º, Àü·«Àû Á¦ÈÞ¿¡ ±â¹ÝÇÑ ÁÖ¿ä ±â¾÷ÀÇ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç ¾îÇÁ·ÎÄ¡
  • Á¶»ç Á¤º¸¿ø
    • 1Â÷ Á¶»ç Á¤º¸¿ø
    • 2Â÷ Á¶»ç Á¤º¸¿ø
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • ±â¼ú ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷ °£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ¿ø°ÝÀÇ·á ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

  • ¼ÒÇÁÆ®¿þ¾î
  • Çϵå¿þ¾î
    • ¸ð´ÏÅÍ
    • ÀÇ·á ÁÖº¯±â±â
    • ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ Àåºñ
    • ±âŸ Çϵå¿þ¾î
  • ¼­ºñ½º
    • ¿ø°Ý »ó´ã
    • ¿ø°Ý °¨½Ã
    • ¿ø°Ý ±³À°
    • ¿ø°Ý Æ®·¹ÀÌ´×
    • ±âŸ ¼­ºñ½º

Á¦6Àå ¼¼°èÀÇ ¿ø°ÝÀÇ·á ½ÃÀå : ÄÉ¾î ¸ðµ¨º°

  • 1Â÷ÀÇ·á(Primary care)
  • ¸¸¼ºÁúȯ °ü¸®
  • ±Þ¼º±â Äɾî
  • Àü¹® Äɾî
  • Á¤½Å°Ç°­ Äɾî

Á¦7Àå ¼¼°èÀÇ ¿ø°ÝÀÇ·á ½ÃÀå : ¸ð´Þ¸®Æ¼º°

  • ½Ç½Ã°£(µ¿±â)
  • Store-and-forward(ºñµ¿±â)
  • ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ

Á¦8Àå ¼¼°èÀÇ ¿ø°ÝÀÇ·á ½ÃÀå : Á¦°ø ¸ðµåº°

  • À¥ ±â¹Ý Ç÷§Æû
  • Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû
  • ¿ÂÇÁ·¹¹Ì½º ¼Ö·ç¼Ç

Á¦9Àå ¼¼°èÀÇ ¿ø°ÝÀÇ·á ½ÃÀå : ±â¼úº°

  • ºñµð¿À ȸÀÇ
  • ¸ð¹ÙÀÏ Çコ(¸ð¹ÙÀÏ Çコ) ¾Û
  • Store-and-forward ±â¼ú

Á¦10Àå ¼¼°èÀÇ ¿ø°ÝÀÇ·á ½ÃÀå : ¿ëµµº°

  • ¿ø°Ý ¹æ»ç¼± Áø´Ü
  • ¿ø°Ý ½ÉÀ庴ÇÐ
  • ¿ø°Ý ÇǺΰú
  • ¿ø°Ýº´¸®Áø´Ü
  • Telepsychiatry
  • ±âŸ ¿ëµµ

Á¦11Àå ¼¼°èÀÇ ¿ø°ÝÀÇ·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Ŭ¸®´Ð
  • ÀÇ»ç Áø·á
  • Áø´Ü ¼¾ÅÍ
  • ȨÇコÄɾî ÇÁ·Î¹ÙÀÌ´õ
  • ÁöºÒÀÚ(º¸Çè ȸ»ç)
  • ȯÀÚ
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦12Àå ¼¼°èÀÇ ¿ø°ÝÀÇ·á ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦13Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕº´»ç¾÷
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦14Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

  • Teladoc Health, Inc.
  • American Well Corporation(Amwell)
  • Doctor On Demand, Inc.
  • MDLive Inc.
  • GlobalMed
  • Vidyo, Inc.
  • Dictum Health, Inc.
  • Koninklijke Philips N.V.
  • GE Healthcare
  • Cerner Corporation
  • Medtronic plc
  • Siemens Healthineers
  • BioTelemetry, Inc.
  • InTouch Health
  • Iron Bow Technologies
  • VSee Lab, Inc.
  • SOC Telemed
  • Cisco Systems, Inc.
KSA 24.08.22

According to Stratistics MRC, the Global Telemedicine Market is accounted for $122.1 billion in 2024 and is expected to reach $333.0 billion by 2030 growing at a CAGR of 18.2% during the forecast period. Telemedicine is the practice of providing healthcare services remotely using telecommunications technology. It allows patients to consult with healthcare professionals via video calls, phone calls, or secure messaging platforms. Telemedicine is used for various purposes, including diagnosis, treatment, follow-ups, and monitoring chronic conditions. It improves access to care, especially for those in rural areas or with mobility issues, reduces travel time and costs, and helps manage healthcare resources more efficiently.

According to the Centers for Disease Control and Prevention (CDC), from 2019 to 2021, telemedicine use among physicians increased from 15.4% to 86.5%.

Market Dynamics:

Driver:

Rising demand for cost-effective healthcare

Telemedicine reduces overall healthcare costs by minimizing hospital visits, travel expenses, and the burden on healthcare facilities. It allows for more efficient use of medical resources and enables patients to receive care from the comfort of their homes. The ability to provide remote consultations and monitoring helps manage chronic conditions more effectively, reducing the need for expensive emergency interventions. This cost-effectiveness is particularly appealing to both patients and healthcare providers, driving widespread adoption of telemedicine solutions.

Restraint:

Data security and privacy concerns

As telemedicine involves the transmission and storage of sensitive patient information, there are risks of data breaches and unauthorized access. Healthcare providers must ensure compliance with regulations like HIPAA, which can be challenging in a digital environment. Patients may be hesitant to use telemedicine services due to fears about the security of their personal health information. Addressing these concerns requires robust cybersecurity measures and clear privacy policies, which can be costly and complex to implement, potentially slowing market growth.

Opportunity:

Growing adoption in developing countries

The growing adoption of telemedicine in developing countries presents a significant opportunity for market expansion. These regions often face challenges in healthcare access, particularly in rural areas. Telemedicine can bridge this gap by providing remote consultations and specialized access. Increasing smartphone penetration and improving internet infrastructure in developing nations facilitate telemedicine adoption. Governments and healthcare organizations in these countries are increasingly recognizing telemedicine's potential to improve healthcare delivery efficiently. This trend opens up new markets for telemedicine providers and technologies, driving innovation and growth in the global market.

Threat:

Technological limitations

Issues such as poor internet connectivity, especially in rural or remote areas, can hinder the quality of video consultations and data transmission. Some patients, particularly older adults, may struggle with using telemedicine technologies, limiting adoption. The lack of standardization in telemedicine platforms and interoperability issues between different systems can create fragmentation in care delivery. Additionally, the inability to perform physical examinations remotely may limit the scope of telemedicine in certain medical specialties, potentially reducing its overall impact and adoption rate.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated telemedicine adoption. Lockdowns and social distancing measures necessitated remote healthcare delivery, leading to rapid growth in telemedicine usage. Regulatory barriers were eased, and reimbursement policies were adjusted to facilitate telemedicine. This shift highlighted telemedicine's potential in maintaining healthcare access during crises and is likely to have a lasting impact on healthcare delivery models.

The real-time (Synchronous) segment is expected to be the largest during the forecast period

The real-time (synchronous) segment is expected to dominate the telemedicine market due to its ability to provide immediate, face-to-face interactions between patients and healthcare providers. This modality closely mimics in-person consultations, allowing for real-time diagnosis, treatment decisions, and patient education. It's particularly effective for urgent care, mental health services, and specialist consultations. The increasing demand for on-demand medical services and the growing comfort of both patients and providers with video conferencing technologies contribute to this segment's dominance.

The software segment is expected to have the highest CAGR during the forecast period

The software segment is anticipated to experience the highest CAGR in the telemedicine market due to rapid technological advancements and increasing digitalization in healthcare. Software solutions, including virtual consultation platforms, electronic health record integration, and AI-powered diagnostic tools, are becoming increasingly sophisticated and user-friendly. These innovations enhance the efficiency and effectiveness of telemedicine services, improving both provider and patient experiences. Additionally, the growing focus on data analytics and AI in healthcare is driving investment in advanced telemedicine software, further accelerating this segment's growth.

Region with largest share:

North America's dominance in the telemedicine market is driven by several factors. The region has a well-developed healthcare infrastructure and high technology adoption rates. Favorable government regulations and reimbursement policies, especially in the United States, have significantly boosted telemedicine usage. The presence of major telemedicine companies and substantial investments in healthcare IT contribute to market growth. The region's high prevalence of chronic diseases and an aging population increase the demand for remote healthcare services. Additionally, the COVID-19 pandemic has accelerated telemedicine adoption in North America, likely cementing its market leadership position for the foreseeable future.

Region with highest CAGR:

The Asia Pacific region is poised to show the highest growth rate in the telemedicine market. This is due to rapid technological advancements, increasing internet penetration, rising healthcare expenditure, and the growing demand for remote healthcare solutions, especially in densely populated countries like India and China. Government initiatives promoting digital healthcare and the adoption of telehealth services amid the COVID-19 pandemic have also accelerated market growth, making Asia Pacific a pivotal region for expanding telemedicine services.

Key players in the market

Some of the key players in Telemedicine market include Teladoc Health, Inc., American Well Corporation (Amwell), Doctor On Demand, Inc., MDLive Inc., GlobalMed, Vidyo, Inc., Dictum Health, Inc., Koninklijke Philips N.V., GE Healthcare, Cerner Corporation, Medtronic plc, Siemens Healthineers, BioTelemetry, Inc., InTouch Health, Iron Bow Technologies, VSee Lab, Inc., SOC Telemed, and Cisco Systems, Inc.

Key Developments:

In May 2024, Medical device giant Siemens Healthineers has announced a $250m investment in a new UK production facility aimed at manufacturing superconducting magnets to be used in Magnetic Resonance Imaging (MRI) devices. Siemens Healthineers has said that the North Oxfordshire facility will both support more than 1,300 jobs in the area and minimise the use of limited and unsustainable materials in making MRIs, such as helium. The facility will be the UK's first-ever home for what the company calls DryCool technology, which reduces the amount of helium required in an MRI scanner from 1,500 litres to under a single litre.

In April 2024, ColonPRO software was introduced for the GI Genius endoscopy system, utilizing artificial intelligence (AI) to improve polyp detection. This latest generation software for the GI Genius intelligent endoscopy system marks a significant leap forward in AI-driven polyp detection.

In January 2024, GlobalMed, a pioneer in virtual care solutions, is pleased to announce the expansion of its CostSimplified virtual healthcare rental program, catering to organizations seeking cost-effective and comprehensive telehealth solutions. The program includes newly added telehealth delivery stations and medical devices, further enhancing GlobalMed's commitment to accessible and affordable virtual care.

Components Covered:

  • Software
  • Hardware
  • Services

Care Models Covered:

  • Primary Care
  • Chronic Disease Management
  • Acute Care
  • Specialty Care
  • Mental Health Care

Modalities Covered:

  • Real-time (Synchronous)
  • Store-and-forward (Asynchronous)
  • Remote Patient Monitoring

Delivery Modes Covered:

  • Web-based Platforms
  • Cloud-based Platforms
  • On-premise Solutions

Technologies Covered:

  • Video Conferencing
  • Mobile Health (mHealth) Apps
  • Store-and-forward Technology

Applications Covered:

  • Teleradiology
  • Telecardiology
  • Teledermatology
  • Telepathology
  • Telepsychiatry
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Physician Practices
  • Diagnostic Centers
  • Home Healthcare Providers
  • Payers (Insurance Companies)
  • Patients
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Telemedicine Market, By Component

  • 5.1 Introduction
  • 5.2 Software
  • 5.3 Hardware
    • 5.3.1 Monitors
    • 5.3.2 Medical Peripheral Devices
    • 5.3.3 Remote Patient Monitoring Devices
    • 5.3.4 Other Hardwares
  • 5.4 Services
    • 5.4.1 Tele-consultation
    • 5.4.2 Tele-monitoring
    • 5.4.3 Tele-education
    • 5.4.4 Tele-training
    • 5.4.5 Other Services

6 Global Telemedicine Market, By Care Model

  • 6.1 Introduction
  • 6.2 Primary Care
  • 6.3 Chronic Disease Management
  • 6.4 Acute Care
  • 6.5 Specialty Care
  • 6.6 Mental Health Care

7 Global Telemedicine Market, By Modality

  • 7.1 Introduction
  • 7.2 Real-time (Synchronous)
  • 7.3 Store-and-forward (Asynchronous)
  • 7.4 Remote Patient Monitoring

8 Global Telemedicine Market, By Delivery Mode

  • 8.1 Introduction
  • 8.2 Web-based Platforms
  • 8.3 Cloud-based Platforms
  • 8.4 On-premise Solutions

9 Global Telemedicine Market, By Technology

  • 9.1 Introduction
  • 9.2 Video Conferencing
  • 9.3 Mobile Health (mHealth) Apps
  • 9.4 Store-and-forward Technology

10 Global Telemedicine Market, By Application

  • 10.1 Introduction
  • 10.2 Teleradiology
  • 10.3 Telecardiology
  • 10.4 Teledermatology
  • 10.5 Telepathology
  • 10.6 Telepsychiatry
  • 10.7 Other Applications

11 Global Telemedicine Market, By End User

  • 11.1 Introduction
  • 11.2 Hospitals
  • 11.3 Clinics
  • 11.4 Physician Practices
  • 11.5 Diagnostic Centers
  • 11.6 Home Healthcare Providers
  • 11.7 Payers (Insurance Companies)
  • 11.8 Patients
  • 11.9 Other End Users

12 Global Telemedicine Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Teladoc Health, Inc.
  • 14.2 American Well Corporation (Amwell)
  • 14.3 Doctor On Demand, Inc.
  • 14.4 MDLive Inc.
  • 14.5 GlobalMed
  • 14.6 Vidyo, Inc.
  • 14.7 Dictum Health, Inc.
  • 14.8 Koninklijke Philips N.V.
  • 14.9 GE Healthcare
  • 14.10 Cerner Corporation
  • 14.11 Medtronic plc
  • 14.12 Siemens Healthineers
  • 14.13 BioTelemetry, Inc.
  • 14.14 InTouch Health
  • 14.15 Iron Bow Technologies
  • 14.16 VSee Lab, Inc.
  • 14.17 SOC Telemed
  • 14.18 Cisco Systems, Inc.
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦